Eton Pharmaceuticals, Inc.

Total Valuation

Eton Pharmaceuticals, Inc. carries a market capitalization of 1.60B, placing it among publicly traded companies globally. Its enterprise value stands at 1.03B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Eton Pharmaceuticals, Inc. currently has 28.29M shares outstanding.

Valuation Ratios

Eton Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 77.57. The price-to-sales ratio is 9.32, and the price-to-book ratio stands at 21.98.

Enterprise Valuation

On an enterprise value basis, Eton Pharmaceuticals, Inc. trades at an EV/EBITDA multiple of 49.22 and an EV/FCF ratio of 31.07. The EV/Sales ratio of 9.72 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 62.92 provides insight into valuation relative to core operating earnings.

Financial Position

Eton Pharmaceuticals, Inc. maintains a current ratio of 1.52, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 62.22, indicating elevated leverage, while an interest coverage ratio of 8.31 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Eton Pharmaceuticals, Inc. posts a return on equity of 35.97 and a return on invested capital of 24.98.

Taxes

Over the trailing twelve months, Eton Pharmaceuticals, Inc. has paid 63,000.00 in income taxes, reflecting an effective tax rate of 0.49.

Stock Price Statistics

Eton Pharmaceuticals, Inc.'s stock has gained approximately 228.74016% over the past 52 weeks. The 50-day moving average sits at 47.74, while the 200-day moving average is 28.28.

Income Statement

Over the trailing twelve months, Eton Pharmaceuticals, Inc. generated 105.60M in revenue and converted that into 12.69M in net income, yielding earnings per share of 0.41. EBITDA reached 20.85M, while operating income came in at 16.31M.

Balance Sheet

Eton Pharmaceuticals, Inc. holds 26.85M in cash and equivalents against 28.99M in total debt, resulting in a net debt position of 1.06M. Total book value stands at 46.59M, with working capital of 23.48M providing operational flexibility.

Cash Flow

Eton Pharmaceuticals, Inc. produced 15.14M in operating cash flow over the past twelve months. After subtracting -15.40M in capital expenditures, free cash flow totaled -268,000.00 - equivalent to -0.01 per share.

Margins

Eton Pharmaceuticals, Inc. operates with a gross margin of 57.87, reflecting its pricing power and cost economics. The operating margin of 15.44 and net profit margin of 12.02 provide insight into operational efficiency.

Dividends & Yields

Scores

Eton Pharmaceuticals, Inc. posts an Altman Z-Score of 9.57, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.